Atorvastatin

A statin that lowers LDL cholesterol by blocking an early step of hepatic cholesterol synthesis.

Medications & hormones

Research records

Historical source snapshot. Not freshly verified, not a recommendation. Study findings, community accounts and app defaults are not interchangeable.

Publication suitability · 2026-10-15: Historical reference only; not a clinical verification. Clinical, regulatory, efficacy, safety and dose claims are not independently established by this review.

Atorvastatin

A statin that lowers LDL cholesterol by blocking an early step of hepatic cholesterol synthesis.

Evidence category: Regulator / guideline. This describes the source category, not approval or certainty.

Regulatory statement in source: FDA-approved.

Atorvastatin is a synthetic HMG-CoA reductase inhibitor, or statin, that lowers LDL cholesterol by blocking an early step in hepatic cholesterol synthesis. It is approved by the FDA to reduce the risk of myocardial infarction, stroke, and other cardiovascular events in adults with elevated cardiovascular risk, and separately to lower LDL cholesterol across several inherited and acquired lipid disorders, including pediatric familial hypercholesterolemia. Its cardiovascular outcome and safety data span numerous large randomized trials.

Benefits reported in the imported source

Reduce risk of myocardial infarction, stroke, revascularization, and angina in adults with elevated cardiovascular risk.
One of the most extensively studied statins, with cardiovascular outcome trials spanning primary and secondary prevention populations.
Approved down to pediatric familial hypercholesterolemia populations under specific age and diagnostic criteria.

Risks and limits

Labeled risk of myopathy and rhabdomyolysis, a rare but serious muscle breakdown reaction.
Not labeled for use during pregnancy or breastfeeding due to potential fetal harm.
Liver enzyme elevations are a labeled adverse reaction requiring periodic monitoring.

Source bottom line: Atorvastatin is an FDA-approved, extensively studied statin for cardiovascular risk reduction and LDL lowering, labeled with monitoring requirements for muscle and liver effects.

Uncertainty: Reference information only. Not medical advice.

Study protocols — reports, not instructions

adults with multiple cardiovascular risk factors, established cardiovascular disease, or hyperlipidemia; pediatric patients ten years and older with heterozygous familial hypercholesterolemia

Reported regimen: oral tablets at a labeled starting dosage of 10 or 20 mg once daily, with a dosage range of 10 mg to 80 mg once daily individualized to therapeutic response
Duration: ongoing daily therapy, with response assessed as early as four weeks after initiation or dose change
Reported outcome: FDA-approved labeling documenting reduced risk of myocardial infarction, stroke, revascularization procedures, and angina, along with LDL cholesterol reduction across studied populations
Source: LIPITOR (atorvastatin calcium) tablet label — DailyMed

Claim provenance

evidence.json#/catalog:medication:atorvastatin/protocols/0

adults and pediatric patients ten years and older across the labeled lipid-disorder and cardiovascular-risk-reduction indications

Reported regimen: full prescribing information covering dosing in hepatic impairment, drug interactions, and pediatric dosing by Tanner stage
Duration: chronic, ongoing oral therapy
Reported outcome: complete FDA-approved prescribing information including labeled risk of myopathy and rhabdomyolysis and monitoring recommendations
Source: LIPITOR full prescribing information — FDA AccessData

Claim provenance

evidence.json#/catalog:medication:atorvastatin/protocols/1

Community and practice descriptions

Accounts of a practice are not evidence of safety or effectiveness. Words such as “standard”, “safe” or “recommended” describe the source account, not verified consensus or this wiki’s advice. Commercial and self-published citations are retained for traceability, not vendor endorsement or independent clinical corroboration.

Historical research outcome: no-verified-description · 2026-10-06

No suitable community description was independently verified in these checks. The entry remains empty; this does not establish that no practice exists elsewhere.

https://www.nhs.uk/medicines/atorvastatin/: no-practice-description — This retrieved source was checked, but no suitable community description was independently verified. Research regimens, expert advice, product identity and efficacy claims were not repurposed.

Pharmacokinetic context

Historical half-life estimate: 20–30 hours. FDA label, Lipitor: parent-drug half-life is about 14 hours, but HMG-CoA reductase inhibitory activity (parent plus active metabolites) has a half-life of 20-30 hours, which is the figure usually quoted for dosing purposes Population/route context and estimates may differ. This is not a schedule or a verified human dosing rule.

Source references

Snapshot provenance

Source ID: catalog:medication:atorvastatin. Commit: adc7684614f9439b41d91a3312b62e7982c7e20e. Review state: historical-not-reverified. Authored links are retained separately from the canonical evidence links in the public data. App templates/defaults and rejected drafts are archived, not deployed.

Related entries and components

None listed.